Contract Manufacturing, General

Under the terms of the agreement, Xellia will acquire substantial parts of the Ben Venue site, including four sterile injectable manufacturing plants, which are not currently operational.

*This article is an opinion piece and does not necessarily represent the views of BioPharm International.

CMC Biologics and River Vision Development announce manufacturing agreement for RV001, a monoclonal antibody to treat Grave’s orbitopathy.

The $19.7 million contract will assist Emergent with the development of cGMP lots of three Ebola mAbs.

The new project will increase fill/finish manufacturing capacity for select products on FDA’s Drug Shortage Index.

Jim Miller, President of PharmSource, speaks with BioPharm International.

Jim Miller, President of PharmSource, spoke with BioPharm International about working with CMOs and CDMOs.

Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

Biomanufacturing capacity expansion uses modular cleanroom design and single-use technologies.

Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.

European CDMOs want into the US market, but entry options are limited.

The trend of exits from the CMO industry looks to be gaining momentum.

With budgets growing, clients see CMOs' costs as less crucial.

Evolving clinical trial research services give biopharmaceutical companies options for full- and functional-services.

The CMO industry's value proposition is limiting its market penetration.

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Changes in company ownership shake up the CMO industry.

Ongoing changes create new opportunities for CROs and CMOs.

Are strategic partnerships in clinical research a model for CMC services?

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Outsourcing is weighing in more as a tactic for cost-cutting, but it is still not the primary weapon.

An innovative approach to capacity management.

Successful management of the CMO/client relationship should include open communication and trust.

BioPlan's outsourcing survey gives insight on top activities, budgets, and growth trends in biopharmaceutical outsourcing.